I. COMMENCED TRADING IN JUNE | ||||||||
Company |
Date |
Date |
Shares/ |
Price | Shares |
Lead, Other |
Gross |
Post- |
INITIAL OFFERINGS | ||||||||
BioXell SpA |
6/9/06 |
6/21/06 |
1.313S |
CHF44 |
5.25 |
Credit Suisse, Bank am Bellevue, Societe Generale, Pacific Growth Equities |
CHF57.8 ($47) |
CHF231.2 |
OncoMethylome |
5/11/06 |
6/26/06 |
3.373S |
€7.50 |
10.45 |
ING, Fortis (co-lead), Kempen & Co. |
€25.3 |
€78.4 |
PuriCore plc |
N/A |
6/27/06 |
45.45S |
£0.66 |
151.8 |
Nomura Code Securities, Nomura International |
£30 |
£100.2 |
Replidyne Inc. |
4/6/06 |
6/28/06 |
4.5S |
$10 |
26.43 |
Merrill Lynch & Co., Morgan Stanley & Co. (co- lead), Cowen & Co., Pacific Growth Equities |
$45 |
$264.3 |
OVERALLOTMENT OPTIONS | ||||||||
Novacea Inc. |
2/10/06 |
6/8/06 |
0.658S |
$6.50 |
22.98 |
Bear, Stearns & Co., Cowen & Co. (co-lead), Pacific Growth Equities, HSBC Securities |
$4.3 |
$149.4 |
Total: $183.3M | ||||||||
Number of IPOs in June: 4 | ||||||||
Average value of June IPOs: $44.75M | ||||||||
Number of IPOs in 2006: 16 | ||||||||
Total raised in IPOs in 2006: $792.28M | ||||||||
Average value of IPOs in 2006: $49.52M | ||||||||
FOLLOW-ON OFFERINGS | ||||||||
Company |
Date |
Date |
Shares/ |
Price | Shares |
Lead, Other |
Gross |
Post-Offering |
Indevus |
2/3/06 |
6/28/06 |
8.05S |
$4.65 |
55.66 |
UBS Investment Bank, CIBC World Markets, JMP Securities, Leerink Swann & Co. |
$37.43 |
$258.8 |
Sangamo |
5/26/06 |
6/15/06 |
3.1S |
$6.50 |
33.94 |
Piper Jaffray & Co. |
$20.15 |
$220.6 |
XenoPort Inc. |
6/6/06 |
6/21/06 |
4.5S |
$17 |
24.40 |
Morgan Stanley & Co., Deutsche Bank Securities, Pacific Growth Equities |
$76.5 |
$414.8 |
Total: $134.08M | ||||||||
Number of follow-on offerings in June: 3 | ||||||||
Average value of June follow-ons: $44.69M | ||||||||
Number of follow-on offerings in 2006: 25 | ||||||||
Total raised in follow-ons in 2006: $2,318.4M | ||||||||
Average value of follow-ons in 2006: $92.74M | ||||||||
Notes: | ||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||||
% Market capitalization is calculated based on the offering price. | ||||||||
Currency conversions are based on exchange rates at the time of the deal. | ||||||||
1 BioXell raised CHF57.8M in an IPO on the Swiss Stock Exchange. Underwriters have an option to purchase up to 196,965 additional shares to cover overallotments. | ||||||||
2 OncoMethylome raised €25.3M in an IPO on the Eurolist exchange. Totals include the underwriters' purchase of 440,000 shares per their overallotment option. | ||||||||
3 PuriCore plc, the parent company of PuriCore Inc. (formerly named Sterilox Techologies), raised £30M in an IPO on the London Stock Exchange. | ||||||||
4 Replidyne raised $45M in an IPO. Underwriters have an option to purchase up to 675,000 additional shares to cover overallotments. | ||||||||
5 Underwriters of Novacea's IPO that priced in May exercised their option to purchase 657,500 additional shares. The IPO totaled about 6.91M shares and $44.9M in gross proceeds. | ||||||||
6 Indevus raised about $37.43M in a follow-on offering. Totals include the underwriters' purchase of 1.05M shares per their overallotment option. | ||||||||
7 Sangamo raised $20.15M in a follow-on offering. The underwriter has an option to purchase up to 465,000 additional shares to cover overallotments. | ||||||||
8 XenoPort raised $76.5M in a follow-on offering. Underwriters have an option to purchase up to 675,000 additional shares to cover overallotments. | ||||||||
II. FILED AND PENDING | ||||||||
Company |
Date |
Shares/ |
Price |
Shares |
Lead, Other |
Value |
INITIAL OFFERINGS | ||||||
Achillion |
4/3/06 |
N/A |
N/A |
N/A |
Cowen & Co., CIBC World Markets (co-lead), JMP Securities |
$75 |
Amicus |
5/17/06 |
N/A |
N/A |
N/A |
Morgan Stanley, Goldman, Sachs & Co. (co-lead), Pacific Growth Equities |
$86.25 |
BioVex |
6/20/06 |
N/A |
N/A |
N/A |
Janney Montgomery Scott, Stifel Nicolaus |
$45 |
Cleveland |
2/17/06 |
N/A |
N/A |
N/A |
Sunrise Securities |
$13.8 |
ImaRx |
5/19/06 |
N/A |
N/A |
N/A |
CIBC World Markets, Jefferies & Co., First Albany Capital |
$75 |
Light Sciences |
4/21/06 |
N/A |
N/A |
N/A |
Cowen & Co., Wachovia Securities (co-lead), Jefferies & Co., Thomas Weisel Partners |
$86.25 |
Molecular |
11/8/05 |
N/A |
N/A |
N/A |
Piper Jaffray & Co., Cowen & Co. (co-lead), Oppenheimer & Co., Roth Capital Partners |
$57.5 |
Osiris |
5/12/06 |
N/A |
N/A |
N/A |
Deutsche Bank Securities |
$80 |
Perlegen |
4/10/06 |
N/A |
N/A |
N/A |
Lehman Brothers, Deutsche Bank Securities (co-lead), Piper Jaffray & Co., Allen & Co. |
$115 |
Pharmasset |
5/9/06 |
N/A |
N/A |
N/A |
Banc of America Securities, UBS Investment Bank (co-lead), JMP Securities |
$75 |
PTC |
3/31/06 |
N/A |
N/A |
N/A |
Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities |
$86.25 |
QuatRx |
2/3/06 |
6S |
$11-$13 |
N/A |
Banc of America Securities, Pacific Growth Equities, Cowen & Co. (co-lead), Lazard Capital Markets |
$72 |
Sucampo |
6/19/06 |
N/A |
N/A |
N/A |
Banc of America Securities, Deutsche Bank Securities (co-lead), Leerink Swann & Co. |
$86.25 |
Trubion |
6/2/06 |
N/A |
N/A |
N/A |
Morgan Stanley & Co., Banc of America (co-lead), Pacific Growth Equities, Lazard Capital Market |
$86.25 |
WITHDRAWN AND POSTPONED | ||||||
Company |
Date Filed/ Date Pulled | Shares/ Units (M) | Price |
Shares Out |
Lead, Other Underwriters | Value |
BioNumerik |
6/9/04/6/9/06 |
5S |
$14-$16 |
N/A |
UBS Investment Bank, Needham & Co., Leerink Swann & Co., Punk, Ziegel & Co. |
$75 |
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. @ This column reflects the shares outstanding following the offering, when disclosed. N/A = Not available, applicable or reported. | ||||||
1 Achillion filed to raise up to $75M in an IPO. | ||||||
2 Amicus filed to raise up to $86.25M in an IPO. | ||||||
3 BioVex filed to raise up to $45M in an IPO. | ||||||
4 Cleveland BioLabs filed to raise up to $13.8M in an IPO. | ||||||
5 ImaRx filed to raise up to $75M in an IPO. | ||||||
6 Light Sciences Oncology filed to raise up to $86.25M in an IPO. | ||||||
7 Molecular Insight filed to raise up to $57.5M in an IPO. | ||||||
8 Osiris filed to raise up to $80M in an IPO. | ||||||
9 Perlegen filed to raise up to $115M in an IPO. | ||||||
10 Pharmasset filed to raise up to $75M in an IPO. | ||||||
11 PTC Therapeutics filed to raise up to $86.25M in an IPO. | ||||||
12 QuatRx filed to raise up to $86.25M in an IPO. Terms were proposed in April. The value is based on the midpoint of that estimate. | ||||||
13 Sucampo filed to raise up to $86.25M in an IPO. | ||||||
14 Trubion filed to raise up to $86.25M in an IPO. | ||||||
15 BioNumerik withdrew its IPO plans, two years after the filing. | ||||||